Conduit Pharmaceuticals
CDTCDT Equity Inc. is a data-driven pharmaceutical development company that identifies and advances high-potential therapeutic assets deprioritized by larger pharmaceutical firms.
Table of contents
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
CDT Equity Inc. is a data-driven pharmaceutical development company that identifies and advances high-potential therapeutic assets deprioritized by larger pharmaceutical firms. The company leverages artificial intelligence, solid-form chemistry, and co-crystallization technologies to enhance drug properties and extend patent life. Operating with a lean, asset-agnostic model, it focuses on pre-clinical and early-stage development to prepare assets for licensing and commercialization partnerships.
CDT Equity positions itself as a specialized re-purposing platform that utilizes AI and proprietary chemistry to unlock value in assets with established Phase I safety data.
Questions, answered.
- What is Conduit Pharmaceuticals's market cap?
- Conduit Pharmaceuticals (CDT) has a market capitalization of $2.0M and trades on NASDAQ.
- Who are Conduit Pharmaceuticals's competitors?
- Conduit Pharmaceuticals's key competitors include Pfizer Inc., Eli Lilly and Company, Instil Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Conduit Pharmaceuticals partner with?
- Conduit Pharmaceuticals's notable partners include AstraZeneca, Sarborg Limited, Manoira Corporation, and others.
- What subsidiaries does Conduit Pharmaceuticals have?
- Conduit Pharmaceuticals's subsidiaries include Conduit UK Management Limited.
- Where is Conduit Pharmaceuticals headquartered?
- Conduit Pharmaceuticals is headquartered in United States of America and employs approximately 7 people. It has been publicly traded since 2023.